Department of Anaesthesiology, Reanimatology and Intensive Care, Medical Faculty, University of Rijeka, Rijeka, Croatia.
Department of Physiology and Immunology, Medical Faculty, University of Rijeka, Rijeka, Croatia ; Clinic of Urology, Clinical Hospital Centre Rijeka, Rijeka, Croatia; Medical Faculty, University of Rijeka, Rijeka, Croatia; Department of Pathology, Medical Faculty, University of Rijeka, Rijeka, Croatia.
Perforin (P) is a prototypical cytotoxic molecule involved in cell-mediated immunity against various pathogens, alloantigens, and particularly different tumours. The purpose of this study was to determine P expression in different lymphocyte subpopulations isolated from peripheral blood and prostate tissue of patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa) and compare it with the P expression found in control group. Twenty subjects were recruited in each of the groups. Prostate mononuclear cells of the BPH and PCa tissues were isolated by enzymatic digestion and gradient density centrifugation, whereas peripheral blood mononuclear cells were isolated by gradient density centrifugation alone. Cells and tissue samples were labelled using monoclonal antibodies against P and different surface antigens (CD3, CD4, CD8, and CD56) and analysed by immunofluorescence and flow cytometry. Total P expression in peripheral blood lymphocytes did not differ significantly between BPH/PCa patients and control group, although the BPH and PCa tissue showed lower P expression level. A negative correlation between prostate-specific antigen (PSA) levels and the overall percentage of P(+) , CD3(+) CD56(-) P(+) , and CD3(-) CD56(+) P(+) cells in the prostate tissue was observed only in PCa patients. Our findings indicate that the low frequency of P(+) lymphocytes, including T, NKT, and NK cells, in the prostate tissue of patients with BPH and, particularly, PCa could be the consequence of local tissue microenvironment and one of the mechanisms involved in the pathogenesis of prostate hyperplasia following malignant alteration.
Written by:
Tokmadžić VS, Tomaš MI, Sotošek S, Laškarin G, Dominović M, Tulić V, Ethorđević G, Sustić A, Mrakovčić-Šutić I. Are you the author?
Reference: Scand J Immunol. 2011 Apr 28. Epub ahead of print.
doi: 10.1111/j.1365-3083.2011.02569.x
PubMed Abstract
PMID: 21535078
UroToday.com Prostate Cancer Section
